Back

Does the efficacy of DOACs in atrial fibrillation differ by heart failure phenotype? a real-world analysis of 315,000 patients

31 August 2026 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Atrial fibrillation in heart failure: predictors and outcomes Heart Failure in Atrial Fibrillation ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Jacob Hicks

Emory Healthcare, Atlanta (United States of America)

7 More presentations in this session

Presentation thumbnail
Comparative outcomes of catheter ablation for atrial fibrillation in heart failure patients with pulmonary hypertension: a propensity-matched analysis
Doctor A. Ajibade (Iowa City, US)
Abstract
Presentation thumbnail
Early vs delayed ablation for atrial fibrillation in heart failure with reduced ejection fraction
Doctor A. Maan (Toledo, US)
Abstract
Presentation thumbnail
Left atrial contraction strain as a predictor of device-detected atrial fibrillation in patients with heart failure with reduced ejection fraction.
Doctor M. Dabrowska (Warsaw, PL)
Abstract
Presentation thumbnail
Epicardial adipose tissue predicts early-stage atrial fibrillation in heart failure with preserved ejection fraction
Mr S. Deng (Taipei, TW)
Abstract
Presentation thumbnail
Effect of sex on atrial fibrillation ablation in heart failure: a post hoc analysis of the RAFT-AF Trial
Doctor R. Parkash (Halifax, CA)
Abstract

Access the full session

Session thumbnail
Atrial fibrillation in heart failure: predictors and outcomes

The Event

Event poster

ESC Congress 2026

31 August 2026 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Anticoagulation with direct-acting anticoagulants decreases the risk of cardiovascular adverse events in patients with heart failure and atrial fibrillation compared to acenocoumarol
29 June 2021
thumbnail
Congress Presentation
Identifying distinct clinical subgroups in heart failure with reduced ejection fraction
21 May 2023
thumbnail
Congress Presentation
Catheter ablation is associated with reduced all-cause mortality in a real-world cohort of patients with atrial fibrillation and heart failure
31 August 2019
thumbnail
Congress Presentation
Newly diagnosed HFpEF in patients with atrial fibrillation: prevalence and impact on antiarrhythmic and antithrombotic management
14 March 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources